VIDEO: Novel treatments in development boost health of photoreceptors
Click Here to Manage Email Alerts
ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Baruch D. Kuppermann, MD, PhD, speaks about some products in development that share a common theme.
Risuteganib (Allegro Ophthalmics) and elamipretide (Stealth BioTherapeutics) are mitochondrial membrane stabilizers, both seemingly effective for improving vision in dry age-related macular degeneration or even early-stage geographic atrophy. Famzeretcel (jCyte) is a novel stem cell therapy for retinitis pigmentosa.
“What they all have in common is that these are conditions with damaged retinas, and these treatments seem to be able to make the retinal cells, the photoreceptors in particular, healthier,” Kuppermann said.
Trials have clarified patient selection criteria, and a new anatomic endpoint has emerged, which the FDA has indicated it is willing to consider.
Collapse
Healio Interviews
Click Here to Manage Email Alerts